ArticleCellular and molecular life sciences : CMLS2025
Prolyl endopeptidase is a multifunctional host factor required for FMDV infection.
Article in Cellular and molecular life sciences : CMLS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Genome-wide CRISPR screen identifies RNF24 as a critical host factor for foot-and-mouth disease virus entry.Frontiers in cell and developmental biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Foot-and-mouth disease virus (FMDV) poses a significant global threat to livestock production, underscoring the urgent need for a deeper understanding of virus-host interactions to develop effective prevention strategies. In this study, we identify prolyl endopeptidase (PREP) as a critical host factor in FMDV infection. We demonstrate that PREP knockout (PREP-KO) significantly enhances host resistance to FMDV infection by upregulating the expression of RIG-I and MDA5 mRNA. Specifically, PREP-KO destabilizes the PUM1 protein via proteasomal and apoptotic degradation pathways, thereby increasing RIG-I promoter activity. Additionally, PREP-KO inhibits the FMDV life cycle at the replication stage. In vivo experiments further reveal that PREP inhibition or knockout provides protection against FMDV infection following a sublethal challenge in mice. Our findings identify PREP as a novel antiviral target, providing valuable insights for development of antiviral therapies and breeding of disease-resistant livestock.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.